Eli Lilly and Company (NYSE:LLY) Reaches New 12-Month High – What’s Next?

Shares of Eli Lilly and Company (NYSE:LLY) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $1,149.10 and last traded at $1,134.1640, with a volume of 1665116 shares changing hands. The stock had previously closed at $1,082.92.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark said it is restoring coverage for Lilly’s blockbuster obesity drug Zepbound and will also cover Lilly’s new obesity pill on standard plans, improving access for millions of patients and reinforcing Lilly’s dominance in the GLP-1 market. Reuters article
• Positive Sentiment: The company announced a $3.83 billion deal to buy three vaccine developers, signaling a major expansion into infectious disease and giving investors a potential new long-term growth engine beyond obesity and diabetes. CNBC article
• Positive Sentiment: Analysts remain upbeat, with reports citing BofA lifting its price target and Wolfe Research reiterating an Outperform rating, which supports the stock’s momentum after recent record highs. Insider Monkey article

Wall Street Analyst Weigh In

LLY has been the subject of a number of analyst reports. HSBC lowered Eli Lilly and Company from a “hold” rating to a “reduce” rating and dropped their price target for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Weiss Ratings lowered Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, May 19th. BMO Capital Markets restated an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Guggenheim restated a “buy” rating and issued a $1,183.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. Finally, CICC Research upped their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research report on Wednesday, February 11th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $1,227.00.

Eli Lilly and Company Stock Up 3.9%

The stock has a market capitalization of $1.06 trillion, a price-to-earnings ratio of 40.00, a PEG ratio of 1.16 and a beta of 0.48. The business has a fifty day moving average of $948.23 and a 200 day moving average of $1,007.67. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the prior year, the firm posted $3.34 earnings per share. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 35.82 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors have recently modified their holdings of the company. Maryland Capital Advisors Inc. acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $25,000. Osbon Capital Management LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $25,000. Basso Capital Management L.P. acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $30,000. Miller Global Investments LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $33,000. Finally, E Fund Management Hong Kong Co. Ltd. raised its stake in shares of Eli Lilly and Company by 342.9% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after acquiring an additional 24 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.